The 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and tetrahydroimidazo [4,5,1-jk] [1, 4] benzodiazepin-2(1H)-one and -thione (TIBO) derivatives were the first compounds shown to be specific human immunodeficiency virus type 1 (HIV-1) inhibitors because of a specific interaction with the HIV-1 reverse transcriptase (RT) (1, 2, 14, 18, 20, 23, 28) . As a rule, the TIBO, HEPT, and other derivatives belonging to the class of nonnucleoside RT inhibitors are exquisitely inhibitory against HIV-1 replication but not replication of HIV-2 or other (retro)viruses. They rapidly lead to the emergency of drug-resistant HIV-1 strains, caused by point mutations in the RT gene, and this emergency of drug-resistant strains is generally regarded as an obstacle to the clinical usefulness of these compounds (4-13, 15-17, 19, 21, 22) . We have recently reported the emergence of mutant HIV-1 strains containing alanine, instead of valine, at position 106 (106-Val3Ala), 181-Tyr3Cys, or 188-Tyr3His in RT when HIV-1-infected CEM cell cultures were exposed to several structurally related HEPT derivatives (5) . Also, Buckheit and Fliakas-Boltz (11) reported the appearance of the 236-Pro3Leu mutation in HIV-1/III Binfected cell cultures treated with HEPT. We have now evaluated a series of 23 highly potent HEPT derivatives against a panel of HIV-1 mutant strains to delineate the structural features of the HEPT derivatives required to afford an antiviral activity spectrum against the mutant virus strains that is as broad as possible.
Abbreviations. Abbreviations used in this paper are as follows: E-EPU, 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil; E-EPU-dM, 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylphenylthio)uracil; E-EPU-S, 5-ethyl-1-ethoxymethyl-6-(phenylthio)-2-thiouracil; E-EPU-SdM, 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylphenylthio)-2-thiouracil; E-EBU, 5-ethyl-1-ethoxymethyl-6-(benzyl)uracil; E-EBU-dM, 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil; E-BPU, 5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil; E-BPU-dM, 5-ethyl-1-benzyloxymethyl-6-(3,5-dimethylphenylthio)uracil; E-BPU-S, 5-ethyl-1-benzyloxymethyl-6-(phenylthio)-2-thiouracil; E-BPU-SdM,
I-EPU, 5-isopropyl-1-ethoxymethyl-6-(phenylthio)uracil; I-EPU-S, 5-isopropyl-1-ethoxymethyl-6-(phenylthio)-2-thiouracil; I-EBU, 5-isopropyl-1-ethoxymethyl-6-(benzyl)uracil; I-BPU, 5-isopropyl-1-benzyloxymethyl-6-(phenylthio)uracil; I-BPU-S, 5-isopropyl-1-benzyloxymethyl-6-(phenylthio)-2-thiouracil; I-HEPU, 5-isopropyl-1-hydroxyethoxymethyl-6-(phenylthio)uracil; I-HEPU-dM, 5-isopropyl-1-hydroxyethoxymethyl-6-(3,5-dimethylphenylthio)uracil; I-HEPU-S, 5-isopropyl-1-hydroxyethoxymethyl-6-(phenylthio)-2-thiouracil; I-HEPU-SdM, 5-isopropyl-1-hydroxyethoxymethyl-6-(3,5-dimethylphenylthio)uracil; and I-HEPU-dM, 5-isopropyl-1-hydroxyethoxymethyl-6-(3,5-dimethylbenzyl)uracil.
The syntheses of the HEPT derivatives have been described previously (2, (23) (24) (25) (26) . CEM cells were obtained from the American Type Culture Collection (Rockville, Md.). HIV-1/ III B was originally obtained from the culture supernatant of persistently HIV-1-infected H9 cells and was kindly provided by R. C. Gallo and M. Popovic (National Cancer Institute, National Institutes of Health, Bethesda, Md.).
To evaluate the activities of the various test compounds against replication of several mutant HIV-1 strains, CEM cells were suspended at 250,000 cells per ml of culture medium and infected with HIV-1/III B , the [2Ј,5Ј-bis-O-(tert-butyldimethylsilyl)-3Ј-spiro-5Љ-(4Љ-amino-1Љ,2Љ-oxathiole-2Љ,2Љ-dioxide)]-␤-D-pentofuranosyl (TSAO)-m 3 T-resistant HIV-1 strain (HIV-1/Lys-138) (9), the nevirapine-resistant HIV-1 strain (HIV-1/ Ala-106) (6), the pyridinone-resistant HIV-1 strain (HIV-1/ Cys-181) (7), the TIBO R82913-resistant HIV-1 strain (HIV-1/Asn-103) (7), the TIBO R82150-resistant HIV-1 strain (HIV-1/Lys-100) (7), the HEPT-resistant HIV-1 strain (HIV-1/His-188) (5), or the pyridinone-plus-BHAP (bisheteroarylpiperazine)-resistant HIV-1 strain (HIV-1/Ile-181) (8) at ϳ100 CCID 50 /ml. The latter mutant virus strains were derived by passage of HIV-1/III B in CEM cell cultures in the presence of the various inhibitors, and the mutations in the RT were verified by DNA sequence analysis as previously described (7, 8) .
Then, 100 l of the infected-cell suspension was added to 200-l microtiter tray wells containing 100 l of an appropriate dilution of the test compounds. After 4 days of incubation at 37ЊC, the cell cultures were examined for syncytium formation. The compound concentration required to inhibit syncytium formation by 50% (EC 50 ) and the compound concentration required to inhibit CEM cell proliferation by 50% were determined. Data in Tables 1 and 2 represent the mean values (Ϯ standard deviations) obtained in two to four independent experiments.
The original HEPT molecule (Table 1) has been chemically modified to new HEPT derivatives that are about 1,000-fold more active against HIV-1 than the parent compound (1, 2). We have now evaluated 23 of the most active HEPT derivatives (EC 50 s ranging from 0.2 to 0.001 M) for their inhibitory activities against wild-type HIV-1/III B and a series of mutant HIV-1 strains containing single mutations in their RTs. HIV-1 mutants with the following mutations in their RTs were included in the present study: 100-Leu3Ile, 103-Lys3Asn, 106-Val3Ala, 138-Glu3Lys, 181-Tyr3Cys, 181-Tyr3Ile, and 188-Tyr3His. Most compounds proved exquisitely inhibitory to wild-type HIV-1, and their cytotoxic concentrations exceeded the antivirally effective concentrations by several orders of magnitude (Table 1) . In general, their activities against HIV-1/100-Ile were reduced by only 2-to 10-fold and their activities against HIV-1/138-Lys were reduced by only 3-to 30-fold (Table 2) , and the EC 50 s of the test compounds were usually far below 1 M. While the activities of most compounds against HIV-1/103-Asn and HIV-1/106-Ala were reduced by more than 2 orders of magnitude, some compounds maintained fairly good activity against HIV-1/106-Ala ( Table  2 ). The activities of the test compounds against HIV-1/181-Cys were generally comparable to those for HIV-1/103-Asn. The HIV-1/181-Ile mutant proved quite refractory to most of the HEPT derivatives containing an isopropyl group at C-5 of the pyrimidine ring, whereas for the HEPT derivatives bearing an ethyl group at C-5 of the pyrimidine ring, the EC 50 against HIV-1/181-Ile was comparable to their EC 50 for HIV-1/181-Cys. The HIV-1/188-His mutant strain proved by far the most resistant to the inhibitory effects of the HEPT compounds ( Table 2 ). The activities of the test compounds against this HIV-1 mutant were at least 10 3 -to 10 4 -fold lower than that for wild-type virus. The EC 50 s of only two compounds, i.e., E-BPU-dM and E-BPU-SdM, against HIV-1/188-His were just below 1 M. The degrees of resistance of the mutant HIV-1 strains are shown in parentheses in Table 2 .
Detailed studies of the structure-activity relationships of HEPT derivatives against the different mutant HIV-1 strains revealed that introduction of sulfur instead of oxygen at the C-2 position of the pyrimidine ring or replacement of the 6-phenylthio by benzyl at the pyrimidine ring did not markedly affect the activities of the compounds against the HIV-1/100-Ile mutant virus or wild-type virus (Table 2 ). When the ethyl at C-5 was replaced by an isopropyl group or when two methyl groups were introduced in the 6-phenylthio or 6-benzyl moiety, less activity against the 100-Ile mutant virus than against the wild-type virus was lost. This feature was particularly striking for I-HEPU-dM and I-HEPU-SdM that proved almost equally active against HIV-1/III B and HIV-1/100-Ile, whereas E-HEPU-dM, E-HEPU-SdM, I-HEPU, and I-HEPU-S were about ϳ5-to 10-fold less active against HIV-1/Ile-100 than wild-type virus. Also, for the HEPU and HEBU derivatives (with R 3 ϭ hydroxymethyl), a greater loss in activity against HIV-1/100-Ile (relative to the wild type) was noted than for the corresponding BPU, EPU, and EBU counterparts (with R 3 ϭ methyl or phenyl). Thus, increasing the lipophilicity of the HEPT derivatives at the C-5 and C-6 positions of the pyrimidine part of the molecule or the acyclic side chain maintained activity against HIV-1/100-Ile.
As a rule, the HEPT derivatives were markedly less active against HIV-1/103-Asn (Table 2) . Increasing the lipophilicity at the pyrimidine C-5 or at the acyclic aliphatic side chain did not affect the antiviral activities of the compounds. However, as also noted for the HIV-1/100-Ile mutant, increasing lipophilicity at the C-6 portion by introducing 3,5-dimethyl groups in the phenyl moiety maintained sufficient activity of the HEPT derivatives against HIV-1/103-Asn. Among the most potent inhibitors of HIV-1/103-Asn were E-BPU-dM and E-EPUdM, with EC 50 s of Ͻ0.1 M.
In general, the HEPT derivatives had a slightly better (twoto threefold) activity against HIV-1/106-Ala than HIV-1/103-Asn (Table 2) . A number of HEPT derivatives (i.e., E-BPU, E-EBU, I-BPU-S, I-EPU-S, and I-EBU) were even six-to eightfold more active against HIV-1/106-Ala than HIV-1/103-Asn. The lowest EC 50 s against HIV-1/106-Ala were obtained for E-EBU-dM, E-BPU-SdM, E-BPU-dM, E-EPU-SdM, and E-EPU-dM (EC 50 s, 0.06 to 0.1 M). Again, a higher lipophilicity at the C-6 position of the pyrimidine appeared to increase activity against HIV-1/106-Ala.
The structure-activity relationship for the HEPT derivatives against the HIV-1/138-Lys mutant strain were almost comparable to those against the HIV-1/100-Ile mutant. In general, the potencies of these compounds were slightly lower (two-to fourfold) against HIV-1/138-Lys than HIV-1/100-Ile ( Table 2) . The most effective HIV-1/138-Lys inhibitors (i.e., E-EPU-dM and E-EBU-dM) were also the most inhibitory to wild-type HIV-1.
The 181-Cys-containing mutant HIV-1 strain showed a substantial loss of sensitivity to most HEPT derivatives ( Table 2 ). The highest antiviral potency was retained by E-BPU-dM, E-EPU-SdM, and E-EBU-dM (EC 50 s, 0.04 to 0.09 M). No obvious structural parameters could be deduced from our study that favored activity of the HEPT derivatives against HIV-1/181-Cys. In general, there was a good correlation between the degree of antiviral potency against wild-type virus and HIV-1/181-Cys. All HEPT derivatives showed a markedly lower activity against HIV-1/181-Ile ( Table 2 ). The decrease of antiviral activity was more pronounced for the 5-isopropylsubstituted HEPT derivatives (10 3 -to 10 4 -fold) than for the 5-ethyl-substituted compounds (10 2 -to 10 3 -fold). There was a trend to a (two-to fivefold) higher antiviral activity, when the C-6 position was made more lipophilic by introducing methyl groups in the phenyl ring. E-BPU-dM, E-BPU-SdM, E-EBUdM, E-EPU-SdM, and E-EPU-dM ranked among the most potent inhibitors of HIV-1/181-Ile with EC 50 s ranging from 0.11 to 0.60 M.
The 188-His mutation in the HIV-1 RT caused a marked decrease of the antiviral efficacies of the HEPT derivatives (Table 2 ). Only few compounds were found to have EC 50 s of Յ1 M (E-BPU-dM, E-BPU-SdM, E-EBU-dM, I-HEPU-dM, and I-HEPU-SdM). Introduction of methyl groups at the 3 and 5 positions of the 6-phenyl moiety counteracted the decrease in antiviral activities of the compounds. Indeed, the 6-(3,5-methylphenyl)-substituted HEPT derivatives E-BPU-dM, E-BPUSdM, and E-EBU-dM were about 20-fold more potent than their unsubstituted counterparts. Replacement of the R 3 ϭ hydroxymethyl or methyl by a phenyl group in the acyclic aliphatic side chain also enhanced the activity by 3-to 15-fold, and this effect was more pronounced when the 6-phenylthio or 6-benzyl group was concomitantly substituted with methyl groups (compare the activities of E-EPU-dM and E-EPU-SdM with those of their corresponding E-BPU-dM and E-BPUSdM derivatives) ( Table 2) .
It is clear that a different structure-activity relationship exists for the HEPT derivatives to inhibit different HIV-1 mutant strains. From our findings, it is evident that it may be difficult to design an HEPT derivative that could efficiently inhibit all the different HIV-1 mutants, but that different HEPT compounds should be combined to achieve an activity spectrum as broad as possible. Three compounds showed the broadest activity spectra against the mutant HIV-1 strains: E-EBU-dM, E-BPU-dM, and E-BPU-SdM (Table 2 ). E-BPU-dM and E-EBU-dM had EC 50 s that were well below or close to 0.002 M (HIV-1/III (HIV-1/188-His) . E-BPU-SdM was four-to sevenfold less inhibitory to HIV-1/181-Cys (EC 50 , 0.32 M) and sixfold less inhibitory to wild-type HIV-1 than the other two compounds. Interestingly, we could identify several HEPT derivatives as still being able to inhibit HIV-1/181-Ile at submicromolar concentrations (8) . Moreover, HIV-1/181-Ile could be completely suppressed in cell culture in the presence of concentrations of 5 g/ml of E-BPU and E-EBU-dM (our unpublished data). The appearance of HIV-1/181-Ile in HIV-1-infected patients has been already found in a few cases of prolonged treatment with HIV-1-specific RT inhibitors (27) . While the HIV-1/181-Ile mutant may prove refractory to most of the HIV-1-specific RT inhibitors, it can still be inhibited by some of the HEPT derivatives, i.e., E-EBU-dM, E-BPU, E-BPU-dM, and E-BPUSdM at EC 50 s well below 1 M.
In conclusion, we have shown that for the HEPT derivatives, different structure-antiviral activity relationships exist, depending on the nature of the mutations in the RTs of the mutant virus strains. These differences cannot be predicted from the activity spectra of the derivatives against wild-type virus. Our observations emphasize the need of a systematic evaluation of the different HIV-1-specific RT inhibitors toward a panel of mutant HIV-1 strains as wide as possible to obtain a better insight in the potential value of the compounds as candidate antiviral drugs to be included in clinical trials.
